目录
- Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
- Chronic intestinal failure and short bowel syndrome in Crohn’s disease
- Natural killer cells in pancreatic cancer stroma
- COVID-19 and its effects on the digestive system
- Neuropilin-1 : A feasible link between liver pathologies and COVID-19
- Hepatitis delta virus: From infection to new therapeutic strategies
- Usefulness of artificial intelligence in gastric neoplasms
- Current impact of viral hepatitis on liver cancer development: The challenge remains
- Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
- Fasudil prevents liver fibrosis via activating natural killer cells and suppressing hepatic stellate cells
- Early genetic diagnosis of clarithromycin resistance in Helicobacter pylori
- Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis
- High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
- Stem cell injection for complex anal fistula in Crohn’s disease: A single-center experience
- Laparoscopic lateral lymph node dissection in two fascial spaces for locally advanced lower rectal cancer
- Disorders of the brain-gut interaction and eating disorders
- Weight loss interventions in living donor liver transplantation as a tool in expanding the donor pool: A systematic review and meta-analysis